1 Supplemental Materials

Figure S1. Information of cynomolgus monkeys and quality control of single-nucleus RNA-seq of NHP skeletal muscle.

- 4 (A) Information of the cynomolgus monkeys used in this study.
- (B) Left, PI and Hoechst double-positive nuclei were enriched by FACS. Right, representative
 images of nuclei after sorting. Scale bars, 50 and 10 μm (zoomed-in image).
- (C) Left, bar plot showing nucleus number of each sample. Right, plot showing the Log₁₀ ratio
 of reads per nucleus and sequencing saturation of each sample.
- 9 (D)Left, box plot showing the unique molecular identifiers (UMIs) in each nucleus. Right, box 10 plot showing the number of genes detected in each nucleus.
- 11 (E) UMAP plot showing the distribution of clusters across all samples.
- 12 (F) Stack bar plot showing the cell proportion of each sample in 14 cell types.
- 13 (G) Bar plot showing the number of nuclei captured across cell types.

Figure S2. Single-nucleus transcriptome profiling of young and old cynomolgus monkey skeletal muscles.

- (A) Box plots showing the cell proportion of each sample across different cell types. The *P* values between old and young groups were calculated using one-sided Wilcoxon Rank Sum
 test.
- 19 (B) Immunofluorescence staining of VWF and SMA in the skeletal muscle from young and old
- 20 monkeys. Representative images are shown on the left; Scale bars, 50 and 20 μ m (zoomed-21 in image). The numbers of VWF-positive and SMA-negative cells were quantified as fold 22 changes in old skeletal muscles vs. in young counterparts and are presented as mean \pm SEMs 23 on the right. n = 8 monkeys for each group.
- (C) Heatmap showing the expression profiles of genes differentially expressed in at least five
 cell types in the monkey skeletal muscle. Only genes with same direction of differential
 expression among different cell types are included.
- (D)Heatmap showing the expression profiles of top 5 differentially expressed genes (DEGs)
 for each cell type.
- (E) Heatmap showing the scaled expression patterns of hotspot genes for muscle diseases related genes in different cell types.
- (F) Network visualization of upregulated core regulatory TFs in different cell types between
 old and young groups. Outer nodes display different cell types and the node size positively
 correlates with the number of target genes differentially expressed in corresponding cell
 types.
- 35 (G)Representative images of negative control of *FOXO3* pre-mRNA labeling in monkey
 36 skeletal muscle by RNA-FISH. Scale bar, 20 μm.

Figure S3. Phenotypic and transcriptomic analyses of human myotubes upon silence or genetic activation of FOXO3.

- (A)MyHC immunofluorescence staining showing the differentiation efficiency of FOXO3^{+/+}
 and FOXO3^{-/-} hMyotubes. Representative images are shown on the left; Scale bar, 100 μm.
- 3 Data are presented as mean \pm SEMs, n = 3 biological replicates for each group.
- 4 (B) Schematic showing the siRNA-mediated knockdown of *FOXO3* in WT hMyotubes.
- 5 (C) FOXO3 immunofluorescence staining in FOXO3^{+/+} and FOXO3^{2SA/2SA} hMyotubes.
 6 Representative images are shown on the left; Scale bar, 50 µm. The numbers of FOXO3 7 positive nuclei were quantified as fold changes (FOXO3^{2SA/2SA} vs. FOXO3^{+/+}) and are
 9 magents because + SEMs as 2 high sized and isotas for each super-
- 8 presented as mean \pm SEMs. n = 3 biological replicates for each group.
- 9 (D)Heatmap showing Euclidean distance of gene expression profiles between FOXO3^{-/-} and
 10 FOXO3^{+/+} hMyotubes.
- 11 (E) Heatmap showing the transcript levels of indicated genes in FOXO3^{+/+} and FOXO3^{-/-} 12 hMyotubes by RT-qPCR. n = 3 biological replicates for each group.
- 13 Supplementary Tables
- 14 **Table S1.** Differentially expressed genes of bulk RNA-seq and snRNA-seq datasets.
- 15 **Table S2.** The marker genes of each cell type in monkey skeletal muscle.
- 16 **Table S3.** Gene sets used in this study.

Table S4. Core regulatory transcription factors of differentially expressed genes in monkey
 skeletal muscle during aging.

- 19 **Table S5.** List of antibodies used in this study.
- 20 **Table S6.** The sequences for primers used in this study.
- 21

Figure S1

Α

No.	Sex	Animal Symbol	Age (years)	No.	Sex	Animal Symbol	Age (years)
1	Female	YF1	5	5	Male	YM1	5
2	Female	YF2	5	6	Male	YM2	5
3	Female	YF3	5	7	Male	YM3	6
4	Female	YF4	4	8	Male	YM4	6
9	Female	OF1	18	13	Male	OM1	18
10	Female	OF2	19	14	Male	OM2	19
11	Female	OF3	19	15	Male	OM3	20
12	Female	OF4	20	16	Male	OM4	21

В Hoechst / PI / Phase 0) After sorting ΡI 102 Hoechst Nucleus number per sample 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0000 - 00000 - 00000 - 0000 - 0000 - 0000 - 0000 - 0000 - 0 С 100 90 80 70 60 50 40 30 20 10 6-Sequencing saturation (%) Reads/Nucleus (Log₁₀) 1 2 2 4 1 2 2 4 0 0 0 OF1 -OF2 -OF3 -OF4 -
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
 K
OM1 -OM2 -OM3 -OM4 -YF1 -YF2 -YM1 -YM2 -YM3 -ΥM4 ΥF3 ΥF4 Sequencing saturation (%) Low quality nucleus Cle D sn 2000 -1500 -1000 -1000 -500 -0 UM number per nucleus 4000 3000 2000 1000 0 0 OM3-OM4-ΥF2-ΥF3-OF3-OF4-0F1-0F2-0F3-0F4-YM2. YM3-ΥM4-OM2 OM3-OM4-YF1. YF2. ΥF3-ΥF4-OF1-OF2-ΥM1. YM2. YM3. ΥM4-OM1. OM2-ΥF1. ΥF4-ΥM1 OM1 G Е F 40000 1.00 YM1 YM2 YM3 YM4 OM1 OM2 OM3 OM4 YF1 YF2 YF3 YF4 OF1 OF2 OF3 OF4 Cell number 30000 Sample proportion 0.75 20000 0.50 10000 0.25 0 UMAP_1 0 Fast IIA Fast IIX Slow I PMF Flb/FAP Flb/FAP Flb/FAP Flb/FAP Flb/FAP Flb/FAP Flb/FAP Todo Pericyte Fld/FAP

Fast IIA -Fast IIX -Slow I -

MuSC -Fib/FAP -

PMF -tSC -

SMC -Pericyte -EC -

Tendo

Mac -T cell -

Adipocyte -

Figure S2



